Related Experiment Video
Updated: Apr 27, 2026
Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
Evolution of lipid management guidelines: evidence might set you free
1An honorary lecturer in the Department of Family Practice at the University of British Columbia in Vancouver, BC. jbosomworth@gmail.com.
Insights
New cardiovascular disease (CVD) risk guidelines simplify lipid management by focusing on evidence-based 10-year risk, not just cholesterol levels. Canadian application requires specific risk assessment tools for better patient understanding.
Area of Science:
- Cardiology
- Preventive Medicine
- Public Health
Background:
- The American Heart Association and American College of Cardiology (AHA-ACC) released new guidelines for cardiovascular risk management.
- These guidelines shift focus from solely low-density lipoprotein (LDL) cholesterol levels to a broader 10-year cardiovascular disease (CVD) risk assessment.
- Understanding the practical application of these guidelines in a Canadian context is crucial.
Purpose of the Study:
- To interpret and adapt the new AHA-ACC cardiovascular risk management guidelines for use in Canada.
- To evaluate the suitability of current risk assessment tools for the Canadian population.
- To explore methods for enhancing patient comprehension and shared decision-making regarding cardiovascular risk.
Main Methods:
- Comprehensive review of the AHA-ACC guidelines and their cited references.
- Independent PubMed searches to identify relevant studies on adjunctive lipid-lowering therapies and risk calculator functionalities.
- Analysis of the applicability of US-based risk calculators versus Canadian-appropriate tools.
Main Results:
- The AHA-ACC guidelines prioritize 10-year CVD risk over LDL levels, abandoning specific LDL treatment targets.
- Emphasis is placed on lifestyle interventions (diet, exercise), with initial efforts to quantify their impact.
- Statins are the primary pharmacologic intervention; combination therapy for lipid lowering is not recommended.
- Framingham risk tables are deemed more suitable for Canadian risk assessment than US-based pooled cohort equations.
- Enhanced risk calculators should incorporate cardiovascular age and graphical representations of risk and interventions.
Conclusions:
- Adopting an evidence-based approach centered on CVD risk simplifies lipid management for healthcare providers.
- Improved patient understanding through enhanced risk communication tools can facilitate informed decision-making.
- Tailoring risk assessment tools to the Canadian population is essential for effective guideline implementation.
Objective:
To understand how the new guidelines for management of cardiovascular risk by the American Heart Association and the American College of Cardiology (AHA-ACC) can be interpreted and used in a Canadian setting.
Sources Of Information:
The AHA-ACC guidelines were reviewed, along with all references. Independent PubMed searches were done to include the addition of other lipid-lowering therapy to statins and the use of medical calculators to enhance patient understanding.
Main Message:
The new AHA-ACC guidelines are based on the best current evidence related to lipid management. This includes use of 10-year cardiovascular disease (CVD) risk as the treatment threshold in place of low-density lipoprotein cholesterol levels, as well as abandonment of low-density lipoprotein treatment targets. There is increased emphasis on dietary and exercise interventions, with the beginning of an effort to quantify the effect of these interventions. Statins are the main drug intervention, and the addition of other drugs to augment lipid lowering is no longer recommended. For application in Canada, Framingham risk tables are more appropriate for risk assessment than the pooled cohort equations used in the United States. Risk calculators for CVD risk should contain information on cardiovascular age and have the ability to represent risk and alternative interventions graphically in order to improve patient understanding and promote informed decision making.
Conclusion:
Focus on the best evidence in CVD risk can simplify lipid management for both the physician and the patient.
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:18Lipids: Dietary Sources and Requirements
01:26Atherosclerosis III: Management
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:06Lipid Digestion